Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Primary:
To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in
reducing the recurrence of ascites.
Secondary:
To evaluate the tolerability and safety of satavaptan in the absence of concomitant diuretic
drugs over a 52-week treatment period in patients with cirrhosis of the liver and recurrent
ascites.
The one-year double blind placebo controlled period is extended up to 2 years in a long term
safety study (PASCCAL-2).